Tumor cells – general cellular pathways

Tumor cells – general cellular pathways refers to the collective set of biological processes and signaling cascades that are dysregulated in malignant cells to promote uncontrolled growth, survival, and dissemination. These pathways encompass the 'Hallmarks of Cancer,' including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and induction of angiogenesis (Hanahan & Weinberg, 2011). Because this term describes a broad category of biological phenomena rather than a single molecular entity, it is not considered a specific therapeutic target in the traditional sense. Instead, it serves as a framework for understanding how various targeted therapies, such as kinase inhibitors or monoclonal antibodies, disrupt specific nodes within these complex networks to treat cancer (NCI, 2023). Therapeutic intervention in these pathways often aims to restore normal regulatory mechanisms or selectively induce apoptosis in cancer cells while minimizing damage to healthy tissues. Common pathways involved include the PI3K/AKT/mTOR, MAPK/ERK, and Wnt/beta-catenin signaling routes, which are frequently mutated or overexpressed in various malignancies (PubMed, 2022). Understanding these general pathways is crucial for the development of combination therapies that can simultaneously hit multiple vulnerabilities within the cancer cell's regulatory network.

Other names

Oncogenic signaling pathwaysCancer cell pathwaysHallmarks of cancerMalignant cellular processes

Inhibition of various intracellular and extracellular signaling cascades, disruption of metabolic homeostasis, and induction of programmed cell death to arrest tumor progression.